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Purpose: The number of patients waiting for kidney transplantation is incessantly in-
creasing, but the number of cadaveric kidney transplantations or ABO-compatible do-
nors is so insufficient that ABO-incompatible kidney transplantation is being per-
formed as an alternative. There are overseas studies and research showing that the 
5-year survival rate and 5-year graft survival rate of ABO-incompatible kidney trans-
plantation are not much different from those of ABO-compatible kidney transplanta-
tion. However, domestic research on the subject is rare. Therefore, we report the results 
of 22 ABO-incompatible kidney transplantation cases performed in our hospital. 
Materials and Methods: This research was from 22 patients in our hospital who under-
went ABO-incompatible kidney transplantation from 15 February 2007 to 20 May 2010.
Results: As yet, there have been no donor graft losses and no deaths after transplanta-
tion. The results of the two groups were analyzed by analysis of covariance of the crea-
tinine value of the recipients at 6 months after the operation, corrected for the pre-
operative value in order to statistically identify whether there were differences in renal 
function after the operation between ABO-compatible and ABO-incompatible kidney 
transplantation. The results of the analysis of covariance showed no statistical differ-
ence in renal function after the operation between the two groups.
Conclusions: Even though there were not many cases, our initial results for ABO-in-
compatible kidney transplantation were positive. Considering the increasing number 
of patients waiting for kidney transplantation, longer-term domestic research studies 
of ABO-incompatible kidney transplantation are necessary. 
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INTRODUCTION
The number of patients with chronic renal failure is in-
creasing along with the aging of the population, and renal 
transplantation is considered to be the most effective treat-
ment for those patients [1]. On a broad scale, renal trans-
plantation is divided into living kidney transplantation 
and cadaveric kidney transplantation. Living kidney 
transplantation in general shows a lower rejection rate, 
and it has the merit of restoring kidney function both in the 
short term and in the long term. Thus, living kidney trans-
plantation is widely performed around the world [2]. In ad-
dition, owing to advanced kidney transplantation pre-
treatment and proper usage of immunosuppression, 
1-year and 5-year survival rates are increasing [3,4].
　Even though the number of patients waiting for kidney 
transplantation is incessantly increasing, the number of 
cadaveric renal transplantations or living donors is in-
sufficient [5], and there are frequent transplantations us-
ing donors after cardiac death or marginal donors who are 
brain-dead. But the number of these is also limited [6,7]. 
　Accordingly, ABO-incompatible kidney transplantation 
is being performed as an alternative. Because ABO-in-
compatible kidney transplantation may result in hyper-Korean J Urol 2010;51:863-869
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acute rejection by ABO antibody, it has been avoided in 
general. But there have been successful results in Japan 
with antibody removal by plasmapheresis and injection of 
gammaglobulin and strong immunosuppressants. This 
method is now being performed instead of using brain-dead 
donors for many patients in Japan [8-11]. Studies in other 
countries, including the research from Tokyo Women's 
University and Johns Hopkins University, have reported 
that the 5-year survival rate and 5-year graft survival rate 
of ABO-incompatible kidney transplantation performed 
since 2000 are little different from those of ABO-compat-
ible kidney transplantation [3,12]. In Korea, however, such 
results are rare. In fact, ABO-incompatible kidney trans-
plantation is hardly conducted for various reasons. 
　Here we report the results of 22 ABO-incompatible kid-
ney transplantations conducted during the latest 3-year 
and 3-month period in our hospital. 
MATERIALS AND METHODS
Of the 83 cases of kidney transplantation in our hospital, 
22 cases of ABO-incompatible kidney transplantation 
were chosen for study, excluding cases of ABO-compatible 
kidney transplantation. The recipients' and donors' gen-
der, age range, and operation year; their relation; the cause 
of chronic renal failure; complications; and the survival 
rate of the graft and patients were recorded.
　This study was based on the comparison of ABO-compat-
ible and ABO-incompatible kidney transplantation. In or-
der to identify whether there were statistically significant 
differences in postoperative renal function between the 
two groups, we used analysis of covariance (ANCOVA), in 
which the dependent variable was the creatinine value of 
the recipients at 6 months after the operation, and the main 
independent variable was ABO-compatibility (the two 
groups). We controlled for the preoperative creatinine 
level. Statistical analysis was conducted by using STATA 
ver. 11.0 (STATA Corp., College Station, TX, US).
　To discern acute rejection, patients who showed certain 
abnormal symptoms from blood tests or clinical experi-
ments were further examined by ultrasound-guided kid-
ney biopsy. Graft failure was defined as the condition that 
the patient could not survive without dialysis and needed 
re-dialysis owing to the recurrence of renal failure or neph-
rectomy after transplantation. Each result was compared 
with that of 61 ABO-compatible kidney transplantations. 
ABO-incompatible kidney transplantation is, as its literal 
meaning indicates, the transplantation of kidney between 
a donor and a recipient with different blood types. 
　The inclusion criteria of our hospital for ABO-incompat-
ible renal donors were the following: systolic blood pressure 
below 140 mmHg; diastolic blood pressure below 90 mmHg; 
quantitative proteinuria test result below 300 mg/24 h; no 
specific findings on the physical examination, general 
urine analysis, urine culture, excretory urography, and CT 
angiography; and results for general blood, serum electro-
lyte, and general biochemistry tests within the normal 
range. The exclusion criteria of our hospital for ABO-in-
compatible renal donors were drug addicts; incurable psy-
chotics; patients with malignancy, abnormal urinary tract 
systems such as vesicoureteral reflex, or systemic disease 
such as severe infection and vascular diseases; and HIV-, 
HBV-, and HCV-positive respondents [13]. In addition, do-
nors who had severe obesity, hypertension at the age of 40 
years or younger, or were 60 years of age or older were also 
excluded. Meanwhile, even though they had a different 
blood type, kidney transplantations from O-type donors to 
other recipients, and from A- or B-type donors to AB-type 
recipients, were not classified as ABO-incompatible cases.
　As kidney transplant pretreatment, rituximab was ad-
ministered once a month intravenously before the oper-
ation without splenectomy. Before September 2008, 375 
mg/m
2 of rituximab was administered; after that date, 187 
mg/m
2 was administered. Plasmapheresis was started 7 to 
14 days before kidney transplantation and plasma volume 
was replaced with 5% albumin. For plasmapheresis just be-
fore the operation or before and after kidney biopsy, equal 
amounts of albumin and fresh frozen plasma were used as 
the replacement in order to supplement the coagulation 
factors. In addition, 100 mg/kg IVIG was administered in-
travenously right after each plasmapheresis. Before trans-
plantation, plasmapheresis was performed every day or ev-
ery other day until the IgG or IgM ABO antibody titer was 
below 8. After transplantation, it was performed se-
lectively only for the following cases for 2 weeks. First, plas-
mapheresis was performed when the IgG or IgM ABO anti-
body titer measurement was over 256 before rituximab 
treatment. Second, it was performed when the ABO anti-
body increased three phases more than the lowest meas-
urement after the operation for 2 weeks. Third, when se-
rum creatinine increased more than 15% to 20% after the 
operation for 2 weeks, plasmapheresis was performed em-
pirically for 2 to 3 days until the target level was reached. 
　Tacrolimus, mycophenolate mofetil (MMF), and pre-
dnisolone were administered from the first plasmaphe-
resis stage. Patients were treated with tacrolimus for 1 
month until their blood concentration reached 8 to 12 ng/ml 
and after that until it reached 4 to 8 ng/ml. Mycophenolate 
was administered during the early 3 months at a dosage 
of 750 mg bid and after that at 500 mg bid. Steroids were 
administered orally at a dose of 0.3 mg/kg/day before the 
operation and then at 5 mg/kg bid intravenously on the day 
of the operation, at 4 mg/kg qd intravenously on the next 
day, at 2 mg/kg qd intravenously on the third day, and at 
0.3 mg/kg/day on the fourth day and then gradually re-
duced by the third month after the operation but kept at 
5 mg/day after that time. 
　Acute rejection was monitored both by the organiza-
tional diagnosis for kidney biopsy rejection with increased 
serum creatinine and by impressive diagnosis for cases not 
showing other reasons for disorder of kidney function clin-
ically but showing symptoms of acute rejection. Because 
the first 3 weeks are a highly dangerous period for anti-
body-mediated rejection, kidney biopsy was performed for Korean J Urol 2010;51:863-869
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TABLE 1. Underlying renal disease and treatment before renal transplantation
　Causes of ESRD
Management
ABO-C KT (n=61) ABO-I KT (n=22)
HD PD Dialysis (−) Total HD PD Dialysis (−)T o t a l
Chronic GN 13 - 6 19 (%) 4 2 1 7
Diabetic nephropathy 11 1 2 14 5 - - 5
Polycystic kidney 6 1 2 10 1 1 1 3
Hypertension 2 - 1   3 1 1 1 3
Renal tuberculosis - - 1   1
Trauma - - 1   1
CAN 1 - -   1
Undetermined etiology 8 2 2 12 4 4
Total 41 4 15 61 (100%) 22 (100%)
ESRD: end stage renal disease, ABO-C KT: ABO-compatible kidney transplantation, ABO-I KT: ABO-incompatible kidney trans-
plantation, HD: hemodialysis, PD: peritoneal dialysis, GN: Glomerulonephritis, CAN: chronic allograft nephropathy
TABLE 2. Donor and recipient ABO type
ABO-C KT (n=61)  ABO-I KT (n=22)
Donors Recipients Patients (n)   Donors Recipients Patients (n)
O A  5 (%) A O  6 (%)
OB   3 B O 5
OA B   1 B A3
OO 1 4 A B3
AA 2 5 A BB 2
BB 1 0 A BA 3
AA B   1
AB AB   2
61 (100%) 22 (100%)
ABO-C KT: ABO-compatible kidney transplantation, ABO-I KT: ABO-incompatible kidney transplantation
all cases when serum creatinine increased more than 15% 
to 20%.
RESULTS
The results of 22 ABO-incompatible kidney transplanta-
tions performed in our hospital over the past 3 years and 
3 months were compared with those of 61 ABO-compatible 
kidney transplantations performed during the same period. 
1. ABO-incompatible kidney transplantation by year
The first ABO-incompatible kidney transplantation was 
performed on February 15, 2007, and there were a total of 
22 cases through May 20, 2010, with 2 cases in 2007, 11 in 
2008, 5 in 2009, and 4 in 2010. 
　A total of 61 cases of ABO-compatible kidney trans-
plantation were performed through May 20, 2010, with 12 
cases in 2007, 19 in 2008, 23 in 2009, and 7 in 2010. 
2. Characteristics of kidney donors and recipients
　1) Range of age and gender: The ABO-incompatible do-
nors’ age range was 19-58 years with an average of 39 years. 
Of the 22 donors, 7 were males and 15 were females. The 
ABO-incompatible recipients’ age range was 33-61 years 
and the average age was 45 years. Fourteen of the recipi-
ents were males, and the remaining 8 were females. The 
ABO-compatible donors’ age range was 19-59 years with 
an average age of 41 years. Thirty of the compatible case 
donors were males and 31 were females. The ABO-compat-
ible recipients’ ages ranged from 22 to 64 years, and the 
average age was 4 years. The gender composition was 45 
males and 16 females.
　2) Cause of renal disease and dialysis before trans-
plantation: The cause of the recipients’ end-stage renal dis-
ease and the status of dialysis before transplantation were 
as shown in Table 1.
　3) Relation between donors and recipients and blood 
analysis: The ABO-incompatible donors’ relations were 
husband (8), sibling (7), wife (2), parents (2), and others (3). 
The ABO-compatible donors’ relations were husband (15), 
sibling (14), wife (6), parents (10), and others (16). The re-
sults of the blood analyses were as shown in Table 2. Korean J Urol 2010;51:863-869
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TABLE 3. Creatinine of donors and recipients 
Time
Creatinine (mg/dl)
ABO-C KT (n=61) ABO-I KT (n=22)
Donors Recipients Donors Recipients
Preoperative 0.8 (0.4-1.1) 8.8 (3.0-25.6) 0.8 (0.6-1.1) 9.4 (3.2-21.6)
Postoperative (1 mo) 1.1 (0.7-1.7) 1.2 (0.6-3.0) 1.1 (0.8-1.6) 1.2 (0.8-1.8)
Postoperative (latest) 1.1 (0.6-1.7) 1.1 (0.7-1.8) 1.1 (0.7-1.5) 1.2 (0.6-1.7)
ABO-C KT: ABO-compatible kidney transplantation, ABO-I KT: ABO-incompatible kidney transplantation
TABLE 4. HLA mismatch number of ABO-I KT and ABO-C KT
HLA mismatch   ABO-C KT   ABO-I KT  
no. (n=61) (n=22)
 0  7 3
 1    1  0
 2    5  1
 3  21  5
 4    7  1
 5  14  9
6    6  3
Total (%) 61 (100%)  22 (100%)
ABO-I KT: ABO-incompatible kidney transplantation, ABO-C 
KT: ABO-compatible kidney transplantation, HLA: human leu-
kocyte antigen
FIG. 1. Comparison of renal function after the operation between ABO-compatible and ABO-incompatible kidney transplantation; 
n=83 cases. Circles are compatible cases, and triangles are incompatible ones.
　4) Operation method and changes in creatinine level: 
There were 17 left donor nephrectomies and 5 right donor 
nephrectomies. With respect to the operation method, 
there were 13 open donor nephrectomy (ODN) procedures 
and 9 hand-assisted laparoscopic donor nephrectomy 
(HALDN) procedures. Creatinine levels were as shown in 
Table 3. The creatinine level of the donors and the recipi-
ents was checked before and 1 month after the operation. 
There was an attempt to compare the creatinine level of 
both recipients and donors after 6 months or 1 year. 
However, even though the recipients’ follow-up (F/U) was 
available for 6 months and 1 year, the donors' follow-up was 
not available on the scheduled date. Therefore, the latest 
creatinine figures for recipients and donors were checked. 
　5) Comparison of renal function after the operation be-
tween ABO-compatible and ABO-incompatible kidney 
transplantation: To compare the ABO-incompatible and 
ABO-compatible groups, we used analysis of covariance in 
which we controlled for the initial level of creatinine. In the 
ANCOVA, the null hypothesis was that the two groups were 
not different; the alternative hypothesis was that they 
differed. Because the p-value for the variable ‘ABO compa-
tibility’ was 0.51, it was not statistically significant. Fig. 
1 further assures such a conclusion. Fig. 1 displays the de-
crease in the creatinine level after the operation in each 
group. We can see that the postoperative result was slightly 
better on average for cases of ABO-incompatible trans-
plants. However, the difference was not statistically 
different. In sum, the statistical analysis (ANCOVA), as 
well as the descriptive statistics, showed no statistical dif-
ference in renal function after the operation between the 
two groups.
　6) Comparison of human leukocyte antigen (HLA) antigen 
mismatched number: We compared the HLA mismatched 
number among 6 antigens, consisting of 1 pair of HLA-A, 
-B, and -DR. The HLA antigen mismatched results for 
ABO-compatible and ABO-incompatible kidney trans-
plantation were as shown in Table 4. Because the number Korean J Urol 2010;51:863-869
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TABLE 5. Complications of recipients
 ABO-C  KT  ABO-I  KT 
　　Complication
(n=61) (n=22)
ACR 12  1
PTDM 12  1
Infection 11  4
Cytomegalovirus infection    8  -
Hyperkalemia    5  -
Hypercalcemia    1  -
Perirenal hematoma    1  -
AMR  1 
ABO-C KT: ABO-compatible kidney transplantation, ABO-I KT:
ABO-incompatible kidney transplantation, ACR: antibody cel-
lular rejection, PTDM: posttransplantation diabetes mellitus, 
AMR: antibody-mediated rejection
FIG. 2. Comparison of renal function after the operation between ABO-compatible and ABO-incompatible kidney transplantation: 
human leukocyte antigen (HLA) mismatch no. 5; n=23 cases.
of cases of ABO-incompatible kidney transplantation was 
too small for drawing inferences in other groups, we com-
pared the postoperative creatinine level between the 
ABO-compatible and -incompatible groups by using HLA 
mismatch no. 5, which had the largest number of ABO-I KT 
cases. The average for 9 ABO-incompatible kidney trans-
plantation cases 1 month after operation was 1.2 (0.8-1.8), 
and the more recent average was 1.1 (0.8-1.8). On the other 
hand, the average for 14 ABO-compatible kidney trans-
plantation cases 1 month after the operation was 1.4 
(0.8-3.0), and the recent average was 1.3 (0.8-1.7). There 
were no graft losses in either case. 
　With the mismatch no. 5 cases, we conducted analysis of 
covariance to discern the effect of ABO-compatibility on the 
postoperative creatinine level. The numbers of cases were 
14 and 9 for ABO-compatible and ABO-incompatible kid-
ney transformation, respectively. As for the previous re-
sults with a greater number of cases, there was no statisti-
cally significant difference between the two groups, with 
the p-value associated with the variable ABO-incompati-
bility being 0.32 from the ANCOVA (Fig. 2). Hence, on the 
basis of these results, we can conclude that there was no 
difference in renal function after the operation between the 
two groups. ABO-incompatible kidney transplantation did 
not show any worse result than ABO-compatible kidney 
transplantation, even under the consideration of HLA 
mismatch.
3. Operative complications
The median time of follow-up was 12 months (range, 1-40 
months), and no particular complications occurred for ei-
ther donors or recipients, except for one recipient whose 
symptoms were not related to ABO-incompatible trans-
plantation.
　In one case, the recipient had delayed graft failure from 
exsanguination during the operation, received hemodial-
ysis for 2 weeks, and was then treated with reduced tacro-
limus. He showed acute cellular rejection IA in the kidney 
biopsy on the 14th day after the operation, but his ABO an-
tibody titer showed the law 2 and then recovered shortly 
after receiving treatment including steroid pulse therapy. 
　Even though there was an antibody-mediated rejection 
related to ABO-incompatible transplantation, the patient 
recovered after plasmapheresis and is in good condition at 
the present. There was 1 post-transplantation case of dia-
betes mellitus, but it has been controlled well by diabetes 
medicine, and 4 cases of urinary tract infection, which were 
cured by antibiotics.
　There were no other complications such as cytomegalovi-
rus infection or carcinoma. On the other hand, there were 
complications of ABO-compatible kidney transplantation 
as shown in Table 5. All complications including acute cel-
lular rejection have been controlled well with proper treat-
ment until now. 
4. Survival rate of grafts and patients
During the follow-up period of 1 to 40 months, there was 
no graft loss, and to date, no patients have died after the 
operation in either the ABO-incompatible or the ABO-com-
patible group.Korean J Urol 2010;51:863-869
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DISCUSSION
The number of patients who are waiting for kidney trans-
plantation is increasing more and more. In the current do-
mestic situation in which cadaveric transplantation is not 
activated, the number of cadaveric grafts is insufficient. 
Organ donation is also not sufficient, and the number of liv-
ing kidney transplantations is not increasing either [5]. 
According to the Korean Network for Organ Sharing 
(KONOS), in 2009, the number of approved living donor 
cases was 800 and the number of marginal donors from 
brain-dead persons was 495, for a combined 1295 cases of 
kidney transplantation. On the other hand, the number of 
patients waiting for kidney transplantation was 2,309 in 
2000, 3,878 in 2003, 5,672 in 2006, and 8,488 in 2009 [5]. 
With the increasing number of patients in need of kidney 
transplantation, domestic hospitals began considering 
ABO-incompatible kidney transplantation. In fact, it has 
been only 10 years since the results for ABO-incompatible 
kidney transplantation became similar to those for ABO- 
compatible kidney transplantation. Although Hume tried 
to perform kidney transplantation between a B-type cadav-
eric donor and an O-type recipient for the first time in 1955, 
he reported that the transplanted kidney did not function 
[14]. Alexandre et al reported the results of 23 cases of 
ABO-incompatible kidney transplantation in 1987, but the 
success rates were lower than for ABO-compatible kidney 
transplantation, showing a 1-year graft survival rate of 
79% and a 1-year patient survival rate of 88% [15,16].
　Until the late 1990s, studies in Japan also reported lower 
records of success of ABO-incompatible transplantation 
than for ABO-compatible kidney transplantation. Since 
2000, however, thanks to advanced immunosuppression, 
there have been reports that the results of ABO-incompat-
ible kidney transplantation show little difference from 
those of ABO-compatible kidney transplantation in the as-
pect of 1-year and 5-year survival rates [3,4]. For example, 
Ishida et al reported obvious advancement in ABO-in-
compatible kidney transplantation by showing that the 
1-year and 5-year graft survival rates of 117 patients using 
tacrolimus and mycophenolate mofetil during 2000 to 2004 
were 94% and 90%, respectively, whereas those of 105 pa-
tients using cyclosporine and zazthioprine performed in a 
single center during 1989 to 1999 were 78% and 73%, re-
spectively [3]. Tydén et al also reported advanced results 
for ABO-incompatible kidney transplantation since 2001 
by showing 60 successful cases by use of a protocol before 
and after the operation that excluded blood antibody by im-
mune absorption and used rituximab instead of splenec-
tomy. They reported no antibody-mediated rejection dur-
ing the follow-up period, which averaged 17 months, and 
that all of the grafts were living except in one case who stop-
ped taking immunosuppression and in one case who died 
[17]. 
　Acute antibody-mediated rejection by blood antibodies 
takes place mainly in the critical period of the early 1 to 3 
weeks just after the operation. Takahashi et al reported 
that all 20 acute antibody-mediated rejections (AMRs) out 
of 441 ABO-incompatible patients occurred within the ear-
ly 3 weeks: 17 (85%) were within 1 week and 3 were within 
2 to 3 weeks [18]. This means that the danger of graft loss 
by ABO-incompatible transplantation is higher during the 
early days after the transplantation. Actually, the data on 
Japan's ABO-incompatible kidney transplantation show 
that the graft loss occurs intensively right after the oper-
ation, and its rate of loss after that period is no different 
from that of ABO-compatible cases [19]. Therefore, the suc-
cess of ABO-incompatible transplantation may be depend-
ent on keeping blood antibodies low at a safe level for the 
early 3 weeks. When antibody-mediated rejection is pre-
vented by proper treatment during the early weeks after 
the operation, the longer term results of ABO-incompatible 
transplantation can be just as good as for ABO-compatible 
kidney transplantation.
　As such, there have been studies from other countries 
providing good results owing to advanced pretreatment 
and immunosuppression. But domestic reports on ABO-in-
compatible kidney transplantation have been very rare, 
except for a few cases. 
　We have performed 22 cases of ABO-incompatible kid-
ney transplantation since February 2007. In all 22 cases, 
rituximab was used instead of splenectomy and plasma-
pheresis was performed before and after the operation as 
mentioned above. In addition, tacrolimus, mycophenolate 
mofetil, and prednisolone were administered in proper 
doses for immunosuppression. 
　Until now, there has not been any graft or patient loss 
during the average follow-up period of 12 months (range, 
1-40 months), except for 1 antibody-mediated rejection. 
Furthermore, there was no statistical difference in renal 
function after the operation between ABO-compatible and 
ABO-incompatible kidney transplantation. 
CONCLUSIONS
Since 2000, there have been reports that the results of 
ABO-incompatible kidney transplantation show little dif-
ference from those of ABO-compatible kidney trans-
plantation in the aspect of 1-year and 5-year survival rates 
owing to the proper usage of immunosuppression. The fol-
low-up survey conducted by our hospital also showed the 
same results concerning patient and transplanted kidney 
survival rates. In addition, the comparison of renal func-
tion according to creatinine after the operation between the 
two groups also showed no statistical difference.
　However, our study was conducted with only 22 cases, 
and the follow-up period was at most 38 months. Thus, fur-
ther research will be necessary with a longer term fol-
low-up period and many more subjects.
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